AstraZeneca - Immuno-oncology treatment paradigms for first-line ES SCLC and unresectable stage III NSCLC Industry Satellite Symposium

Treating 1L ES-SCLC with immuno-oncology: A clinical case study

Lecture Time
17:15 - 17:30
Speakers
  • A. Addeo (Geneva, Switzerland)
Session Name
AstraZeneca - Immuno-oncology treatment paradigms for first-line ES SCLC and unresectable stage III NSCLC
Room
Channel 1
Date
Thu, 25.03.2021
Time
16:10 - 17:40
Authors
  • A. Addeo (Geneva, Switzerland)